Hepatitis

News

GSK hails 'unprecedented' cure rates with hep B drug

The B-Well trials of GSK's bepirovirsen position the antisense drug as a "major step towards a cure for hepatitis B infection," according to experts.

News

Gilead claims first FDA nod for a hepatitis D therapy

At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.

News

GSK enlists local aid for Chinese rollout of hep B drug

GSK has partnered Sino Biopharm to make the most of the Chinese launch of hepatitis B drug bepirovirsen, currently under NMPA review.

News

GSK eyes October FDA verdict on chronic hep B drug

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.

R&D

graphic illustration of liver within human body on abstract background with DNA chain

Navigating the complexities of drug development in hepatolog...

In the realm of medical research, liver disease remains a complex and often overlooked field.

News

Bluejay hatches $182m funding egg for hepatitis drugs

Bluejay Therapeutics has completed a sizeable third-round financing, raising $182 million that will be used for clinical trials of its drug candidates for hepatitis.

GSK hails 'unprecedented' cure rates with hep B drug

Gilead claims first FDA nod for a hepatitis D therapy

GSK enlists local aid for Chinese rollout of hep B drug

GSK eyes October FDA verdict on chronic hep B drug

Navigating the complexities of drug development in hepatolog...

Bluejay hatches $182m funding egg for hepatitis drugs

Ipsen charts $1.75bn course for Kartos acquisition

Discover a new era of healthcare panel engagement: Grounded ...

Hepatitis

Editor's Picks